Hikma stock holds focus as 2025 results frame 2026 trading

Hikma stock, representing Hikma Pharmaceuticals plc (GB00B128J450), is still being judged against its latest full-year base: revenue reached $3.12 billion in 2025, adjusted EBIT was $678 million, and adjusted diluted EPS was 199 cents. Those figures matter because they set the comparison point for 2026 trading and for any rerating of the London-listed group.

Revenue above $3 billion

According to Hikma, 2025 revenue of $3.12 billion compared with $2.97 billion in 2024, a rise of about 5.1% year on year. Adjusted EBIT of $678 million in 2025 also marked an increase from $631 million in 2024, while the adjusted EBIT margin improved to 21.7% from 21.3%.

The same results also showed adjusted diluted EPS of 199 cents in 2025 versus 185 cents in 2024. That 14-cent increase is a useful benchmark for the stock because it links operational progress to per-share earnings power.

Margins near 22%

Hikma's reported margin profile remains the key investor lens after 2025. The company said the adjusted EBIT margin for the year reached 21.7%, which gives the market a concrete level to test against any 2026 earnings commentary.

For a stock that trades on earnings quality as much as headline growth, the combination of $3.12 billion in revenue, $678 million in adjusted EBIT, and 199 cents in adjusted diluted EPS provides the cleanest current frame. A higher margin base usually leaves more room for small changes in product mix, pricing, or operating leverage to show up in the share price.

Injectables still matter

The most commercially important business line is Hikma's injectables franchise, which the company has repeatedly identified as a core earnings driver in its annual reporting. The segment matters because it supports the group mix that helped lift adjusted EBIT to $678 million in 2025.

That business is also central to the company's operating profile because investors usually read it alongside the group margin, not in isolation. In practical terms, the stock's sensitivity still runs through the balance between volume growth and margin durability in higher-value products.

London listing pressure point

Hikma Pharmaceuticals plc is listed in London, and the stock therefore has to be read through sterling market expectations as well as the group's dollar-denominated reporting base. The latest annual figures give the market a dated reference set: revenue of $3.12 billion, adjusted EBIT of $678 million, and adjusted diluted EPS of 199 cents in 2025.

Those numbers are the anchor for the next comparison point. If 2026 updates keep the same earnings trajectory, the market will compare them directly with the 2025 base rather than with a broader sector narrative.

2025 numbers set the base

Hikma's annual report also showed that the group improved from 2024 on each of the main operating metrics highlighted above. Revenue rose by $150 million year on year, adjusted EBIT increased by $47 million, and adjusted diluted EPS added 14 cents.

That combination is important because it gives the stock a measurable starting line: a revenue base above $3 billion, an EBIT margin above 21%, and EPS close to 200 cents. For investors following the name, those are the figures that matter most until the next formal update.

Injectables drive the mix

Hikma's injectables business remains the representative product line for the group because it sits at the center of the company's margin structure. In the 2025 annual results, that broader operating mix supported adjusted EBIT of $678 million and an adjusted EBIT margin of 21.7%.

For readers tracking the stock, the product angle matters only insofar as it explains why the company can convert revenue growth into earnings growth. The 2025 numbers suggest that the mix was good enough to lift both profit and margin at the same time.

Stock base in pounds

The stock trades in London, but the most recently evidenced market-relevant values available here are the 2025 operating numbers: $3.12 billion of revenue, $678 million of adjusted EBIT, and 199 cents of adjusted diluted EPS. Those figures are the best current reference for the share until a newer market quote or trading update is published.

The comparison set is clear: 2025 revenue was $150 million higher than 2024, adjusted EBIT was $47 million higher, and adjusted diluted EPS improved by 14 cents. That is the level of quantified progress the market can price against in 2026.